Direct-acting Anticoagulants in Chronic Coronary Syndromes
Direct-acting oral anticoagulants (DOACs) are easier to use, safer than and as effective as vitamin K antagonists (VKA) in the treatment of non-valvular AF (NVAF). Because of their favourable safety profile and easier use than VKAs, DOACs as anti-thrombotic therapy may have a role in the management...
Guardado en:
Autores principales: | Emmanuel Sorbets, Philippe Gabriel Steg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/02fb7af57d97422ebc19c8dc1b480c2b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Antithrombotic Therapy in Complex Percutaneous Coronary Intervention Patients Requiring Chronic Anticoagulation
por: Despoina-Rafailia Benetou, et al.
Publicado: (2021) -
Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?
por: Mahmoud Abdelnabi, et al.
Publicado: (2020) -
Direct Oral Anticoagulants Concentration Testing in Clinical Practice for High-Risk Patients with AF
por: K Pukite, et al.
Publicado: (2020) -
2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome
por: Jack Wei Chieh Tan, et al.
Publicado: (2021) -
Percutaneous Coronary Intervention for Chronic Total Occlusion
por: Giovanni Maria Vescovo, et al.
Publicado: (2020)